Supplementary Table 3. Sensitivity analyses for the association between pioglitazone use and bladder cancer
Based on an observed HR of 1.63, a pioglitazone exposure prevalence of 7.3%, and a confounder prevalence of 20%. Blue line: observed hazard ratio (HR); Green line: lower bound of the confidence intervals. OR Exposure-Confounder : odds ratio for the exposure-confounder association;
RR Confounder-Disease : relative risk for the confounder-disease association.
Exposure-confounder and confounder-disease associations to the right of the curves would be necessary to bring the association down to the null. We conducted a marginal structural Cox proportional hazards model to address potential residual time-dependent confounding over the 14.5-year follow-up period, a method designed to adjust for time-dependent confounding associated with time-varying exposures. 1 2 It first involved fitting two pooled logistic regression models to estimate the conditional probability of being exposed to pioglitazone and rosiglitazone given previous treatment history at each 30-day intervals during follow-up; one for the numerator and the other for the denominator of the stabilized inverse-probability-of-treatment weights (IPTWs). The numerator model included baseline covariates (age, sex, year of cohort entry, body mass index, smoking status, alcohol-related disorders, haemoglobin A1c, duration of treated diabetes, prior bladder conditions, history of cancer [other than non-melanoma skin cancer], the presence of a urine protein test, and Charlson comorbidity score ) and follow-up time. The second denominator model included covariates (age, year of cohort entry, body mass index, smoking status, alcohol-related disorders, haemoglobin A1c, bladder conditions, cancer [other than non-melanoma skin cancer], the presence of a urine protein test, and Charlson comorbidity score) measured at each time interval and follow-up time. In both treatment models, the follow-up time variable was modelled using a restricted cubic spline with five knots to reduce bias due to model misspecification from linearity assumptions. 3 We also estimated inverse probability of censoring weights (IPCWs) in a similar fashion. Stabilized IPTW and IPCW for each patient were computed using the predicted probabilities from the two treatment and censoring models. The product of these stabilized IPTWs and IPCWs was then used to reweight the cohort, in which we estimated the hazard ratios of bladder cancer associated with the use of pioglitazone and rosiglitazone, with 95% confidence intervals calculated using robust variance estimators. 2 
